Gufic Biosciences
Ticker > Company >

Gufic Biosciences share price

Gufic Biosciences Ltd.

NSE: GUFICBIO BSE: 509079 SECTOR: Pharmaceuticals & Drugs  1.05 L   1.18 K   324

365.00
-1.35 (-0.37%)
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 371.7

Today's Low

₹ 361.8

52 Week High

₹ 501.1

52 Week Low

₹ 285

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3660.13 Cr.

Enterprise Value

₹ 3963.69 Cr.

No. of Shares

10.03 Cr.

P/E

59.86

P/B

5.97

Face Value

₹ 1

Div. Yield

0.03 %

Book Value (TTM)

₹  61.17

CASH

₹ 13.47 Cr.

DEBT

₹ 317.03 Cr.

Promoter Holding

72.52 %

EPS (TTM)

₹  6.1

Sales Growth

16.8%

ROE

19.57 %

ROCE

17.37%

Profit Growth

8.07 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year16.8%
3 Year18.26%
5 Year18.12%

Profit Growth

1 Year8.07%
3 Year24.88%
5 Year31.46%

ROE%

1 Year19.57%
3 Year29.57%
5 Year28.02%

ROCE %

1 Year17.37%
3 Year29.3%
5 Year27.79%

Debt/Equity

0.5953

Price to Cash Flow

-490.82

Interest Cover Ratio

8.5307

CFO/PAT (5 Yr. Avg.)

0.628569498305083

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 72.52 0.00
Mar 2025 72.51 0.00
Dec 2024 72.51 0.00
Sep 2024 72.51 0.00
Jun 2024 72.50 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 24.8771611532785% for the Past 3 years.
  • The company has shown a good revenue growth of 18.2623766425272% for the Past 3 years.
  • Company has been maintaining healthy ROE of 29.5732082740092% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.2959105499848% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 8.5307.
  • The company has an efficient Cash Conversion Cycle of 18.8515 days.
  • The company has a high promoter holding of 72.52%.

 Limitations

  • Company has negative cash flow from operations of -7.4571.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 202.81 204.18 207.79 205.02 226.91
Total Expenditure 167.03 165.56 173.85 178.38 194.58
Operating Profit 35.78 38.62 33.94 26.64 32.34
Other Income 1.26 0.11 1.86 0.38 0.89
Interest 4.62 5.18 4.91 8.4 9.23
Depreciation 4.31 4.3 4.62 7.84 7.72
Exceptional Items 0 0 0 0 0
Profit Before Tax 28.11 29.26 26.28 10.78 16.28
Tax 7.25 7.49 6.96 2.81 4.2
Profit After Tax 20.86 21.78 19.33 7.98 12.07
Adjusted EPS (Rs) 2.08 2.17 1.93 0.8 1.2

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 378.84 487.7 779.16 690.62 806.67
Total Expenditure 326.72 403.78 631.13 555.97 660.79
Operating Profit 52.12 83.92 148.03 134.65 145.87
Other Income 5.79 3.73 3.1 2.57 2.18
Interest 13.91 13.63 5.37 8.22 15.36
Depreciation 13.86 16.31 18.93 22.28 17.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 30.13 57.71 126.84 106.72 115.67
Tax 7.44 13.48 31 27.02 29.54
Net Profit 22.69 44.23 95.84 79.7 86.14
Adjusted EPS (Rs.) 2.34 4.56 9.89 8.22 8.59

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.69 9.69 9.69 9.69 10.03
Total Reserves 119.63 163.74 259.42 338.11 522.53
Borrowings 19.54 35.43 47.98 190.68 153.96
Other N/C liabilities 18.24 19.54 17.9 33.5 33.97
Current liabilities 239.77 190.96 186.4 288.21 372.05
Total Liabilities 406.88 419.36 521.4 860.19 1092.54
Assets
Net Block 82.58 99.97 115.17 159.57 158.89
Capital WIP 30.61 13.4 40.87 169.59 307.06
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.78 1.79
Loans & Advances 18.54 17.12 43.65 64.35 23.12
Other N/C Assets 1.84 0.98 0.95 1.8 1.21
Current Assets 273.31 287.88 320.75 464.11 600.47
Total Assets 406.88 419.36 521.4 860.19 1092.54
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 30.13 57.71 126.84 106.72 115.67
Adjustment 24.63 30.79 23.18 29.64 34.15
Changes in Assets & Liabilities 2.48 8.15 -10.72 -135.25 -130.23
Tax Paid -10.14 -9.4 -33.06 -27.7 -27.04
Operating Cash Flow 47.1 87.25 106.24 -26.59 -7.46
Investing Cash Flow -42.53 -6.69 -94.59 -190.73 -102.4
Financing Cash Flow -4.21 -78.62 -6.24 234.31 82.38
Net Cash Flow 0.37 1.94 5.41 16.99 -27.48

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 72.50 72.51 72.51 72.51 72.52
gufic private limited 10.16 10.16 10.16 10.16 10.16
jayesh pannalal choksi 24.62 24.62 24.62 24.62 24.62
pranav jayesh choksi 7.25 7.25 7.25 7.25 7.25
vipula jayesh choksi 10.01 10.01 10.01 10.01 10.01
zircon teconica private l... 20.47 20.47 20.47 20.47 20.47
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 27.50 27.49 27.49 27.49 27.48
investor education and pr... 0.25 - - - 0.26
jagdish n master 1.53 1.52 1.49 1.44 1.43
llp 0.71 0.71 0.71 0.74 0.71
motilal oswal financial s... 3.32 3.32 3.32 3.32 3.32
motilal oswal small cap f... 1.05 1.05 1.08 1.38 1.38
investor education and pr... - 0.25 0.29 0.26 -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit ICRA
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q3FY22
Concall Q2FY22
Concall Q2 FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY21
Presentation Q2FY24
Presentation Q2FY21

Company News

Gufic Biosciences makes investment in Gufic Ireland 26 Aug, 12:38 PM Gufic Biosciences - Quaterly Results 13 Aug, 7:01 PM Gufic Biosciences - Quaterly Results 13 Aug, 7:01 PM Gufic Biosciences - Quaterly Results 30 May, 7:37 PM Gufic Biosciences - Quaterly Results 30 May, 7:37 PM Gufic Biosciences informs about transcript of earnings call 21 Feb, 4:51 PM Gufic Biosciences - Quaterly Results 14 Feb, 6:27 PM Gufic Biosciences - Quaterly Results 14 Feb, 6:27 PM Gufic Biosciences informs about conference call 12 Feb, 4:40 PM Gufic Biosciences makes investment in Veira Life FZE 14 Jan, 9:42 AM Gufic Biosciences - Quaterly Results 14 Nov, 7:33 PM Gufic Biosciences - Quaterly Results 14 Nov, 7:33 PM Gufic Biosciences - Quaterly Results 14 Aug, 3:20 PM Gufic Biosciences - Quaterly Results 14 Aug, 3:20 PM Gufic Biosciences informs about conference call 9 Aug, 5:12 PM Gufic Biosciences informs about analyst meet 6 Aug, 3:02 PM Gufic Biosciences informs about outcome of board meeting 27 Jun, 5:30 PM Gufic Biosciences - Quaterly Results 29 May, 8:54 PM Gufic Biosciences - Quaterly Results 29 May, 8:54 PM Gufic Biosciences incorporates Wholly Owned Subsidiary 4 Apr, 10:40 AM Gufic Biosciences informs about demise of director 2 Apr, 3:29 PM Gufic Biosciences - Quaterly Results 14 Feb, 5:57 PM Gufic Biosciences - Quaterly Results 14 Feb, 5:57 PM Gufic Biosciences informs about compliance certificate 9 Jan, 3:56 PM Gufic Biosciences informs about transcript of earnings call 23 Nov, 3:24 PM Gufic Biosciences incorporates subsidiary in India 20 Nov, 9:58 AM Gufic Biosciences - Quaterly Results 9 Nov, 5:57 PM Gufic Biosciences informs about outcome of board meeting 11 Oct, 4:44 PM Gufic Biosciences granted patent for invention 15 Sep, 10:30 AM Gufic Biosciences gets nod for Parecoxib Sodium 40mg injection 12 Sep, 10:10 AM Gufic Biosciences informs about press release 2 Sep, 4:05 PM Gufic Biosciences - Quaterly Results 11 Aug, 5:27 PM Gufic Biosciences - Quaterly Results 11 Aug, 5:27 PM Gufic Biosciences gets nod from NMPA for PRILOCAINE API 17 Jun, 10:33 AM Gufic Biosciences informs about press release 7 Jun, 4:08 PM Gufic Biosciences informs about analyst meet 1 Jun, 2:39 PM Gufic Biosciences - Quaterly Results 29 May, 6:57 PM Gufic Biosciences - Quaterly Results 29 May, 6:57 PM Gufic Biosciences incorporates wholly owned subsidiary in Ireland 4 Mar, 4:31 PM Gufic Biosciences informs about incorporation of a wholly owned subsidiary company 4 Mar, 3:54 PM Gufic Biosciences - Quaterly Results 10 Feb, 6:33 PM Gufic Biosciences - Quaterly Results 10 Feb, 6:33 PM Gufic Biosciences - Quaterly Results 11 Nov, 7:30 PM Gufic Biosciences - Quaterly Results 11 Nov, 7:30 PM Gufic Biosciences informs about proceedings of AGM 3 Sep, 3:28 PM Gufic Biosciences - Quaterly Results 11 Aug, 9:14 PM Gufic Biosciences - Quaterly Results 11 Aug, 9:14 PM Gufic Biosciences targets to capture major share of Rs 3000 crore lyophilized antibacterial market in India 7 Jun, 12:29 PM Gufic Biosciences’ promoter intends to sell 4.68 lakh shares of his holding 2 Jun, 11:06 AM Gufic Biosciences informs about press release 24 May, 2:16 PM

Gufic Biosciences Stock Price Analysis and Quick Research Report. Is Gufic Biosciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Gufic Biosciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Gufic Biosciences has a PE ratio of 60.1764541891471 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Gufic Biosciences has ROA of 8.822% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Gufic Biosciences has a Current ratio of 1.614.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Gufic Biosciences has a ROE of 19.5681%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Gufic Biosciences has a Debt to Equity ratio of 0.5953 which means that the company has low proportion of debt in its capital.

  • Sales growth: Gufic Biosciences has reported revenue growth of 16.803% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Gufic Biosciences for the current financial year is 18.0832530749727%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Gufic Biosciences is Rs 0.1 and the yield is 0.0273%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Gufic Biosciences is Rs 6.0979. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Gufic Biosciences in Ticker for free. Also, one can get the intrinsic value of Gufic Biosciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Gufic Biosciences FAQs

Q1. What is Gufic Biosciences share price today?
Ans: The current share price of Gufic Biosciences is Rs 366.95.

Q2. What is the market capitalisation of Gufic Biosciences?
Ans: Gufic Biosciences has a market capitalisation of Rs 3679.68308267 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Gufic Biosciences?
Ans: The PE ratio of Gufic Biosciences is 60.1764541891471 and the P/B ratio of Gufic Biosciences is 5.99849281635736, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Gufic Biosciences share?
Ans: The 52-week high share price of Gufic Biosciences is Rs 504.25, and the 52-week low share price of Gufic Biosciences is Rs 298.8.

Q5. Does Gufic Biosciences pay dividends?
Ans: Currently, Gufic Biosciences pays dividends. Dividend yield of Gufic Biosciences is around 0.0273%.

Q6. What are the face value and book value of Gufic Biosciences shares?
Ans: The face value of Gufic Biosciences shares is Rs 1, while the book value per share of Gufic Biosciences is around Rs 61.1737. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Gufic Biosciences?
Ans: Gufic Biosciences has a total debt of Rs 317.0345 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Gufic Biosciences?
Ans: The ROE of Gufic Biosciences is 19.5681% and ROCE of Gufic Biosciences is 17.3688%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Gufic Biosciences a good buy for the long term?
Ans: The Gufic Biosciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Gufic Biosciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Gufic Biosciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Gufic Biosciences’s financials?
Ans: You can review Gufic Biosciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Gufic Biosciences

Gufic Biosciences Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Gufic Biosciences Ltd. is a leading pharmaceutical company that specializes in the development, manufacturing, and marketing of a wide range of healthcare products. With a strong presence in both domestic and international markets, Gufic Biosciences is recognized for its high-quality offerings and its commitment to innovative healthcare solutions.

Established in [year], Gufic Biosciences has emerged as a trusted name in the pharmaceutical industry. The company operates across various therapeutic segments, including pain management, diabetes care, cardiology, dermatology, and more. Gufic Biosciences' products are manufactured at state-of-the-art facilities that adhere to international quality standards.

Share Price Analysis - Gufic Biosciences Ltd.

The share price of Gufic Biosciences Ltd. reflects the market perception and investors' confidence in the company's growth potential. Investors can track the share price through various platforms, including our website, where we provide real-time stock prices and historical data.

Our pre-built screening tools allow investors to analyze and compare the share price of Gufic Biosciences against industry peers, helping them make informed investment decisions. These tools provide insights into historical trends, price movements, and market performance.

Balance Sheet Analysis - Gufic Biosciences Ltd.

The balance sheet of Gufic Biosciences Ltd. provides a snapshot of the company's financial position at a given point in time. It reflects the assets, liabilities, and shareholders' equity of the company. Investors can access the company's balance sheet on our website, where we provide downloadable annual reports.

For long-term investors looking for stock analysis, our premium features offer fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help investors assess the financial health and intrinsic value of Gufic Biosciences.

Annual Report Analysis - Gufic Biosciences Ltd.

The annual report of Gufic Biosciences is a comprehensive document that provides detailed information about the company's operations, financial performance, and future outlook. It contains key financial statements, management discussions, and analysis of risks and opportunities.

As a long-term investor, it is crucial to review the annual report to gain insights into the company's strategy, competitive positioning, and growth prospects. At our website, we provide downloadable annual reports of Gufic Biosciences, allowing investors to analyze the company's performance in detail.

Dividend Analysis - Gufic Biosciences Ltd.

Dividends play an essential role in long-term investments, as they reflect the company's ability to generate profits and return value to shareholders. Gufic Biosciences has a track record of consistently rewarding its shareholders through dividends.

Investors can assess the dividend history and dividend yield of Gufic Biosciences using our pre-built screening tools. These tools provide an overview of the company's dividend payouts, helping investors make informed decisions based on their income requirements and investment objectives.

Quarterly Result Analysis - Gufic Biosciences Ltd.

The quarterly results of Gufic Biosciences provide an update on the company's financial performance and its ability to meet its targets. Investors can access the quarterly results on our website, where we provide downloadable financial statements and reports.

Our premium features enable investors to perform in-depth analysis of the quarterly results using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools assist investors in understanding the key drivers behind the company's financial performance and its future growth prospects.

Stock Price Analysis - Gufic Biosciences Ltd.

The stock price of Gufic Biosciences is influenced by various factors, including market dynamics, industry trends, company performance, and investor sentiment. Investors can track the stock price through our website, where we provide real-time data and detailed price charts.

Additionally, our pre-built screening tools allow investors to analyze and compare the stock price of Gufic Biosciences against industry peers. These tools provide insights into historical trends, price movements, and market performance, aiding investors in their decision-making process.

News Analysis - Gufic Biosciences Ltd.

Keeping up with the latest news and updates about Gufic Biosciences is essential for long-term investors. Our website provides a dedicated news section where investors can access the latest announcements, press releases, and industry updates related to Gufic Biosciences.

Staying informed about the company's developments, product launches, collaborations, and regulatory updates can help investors make well-informed investment decisions. Our website serves as a reliable source of news and information for investors interested in Gufic Biosciences.

Concall Transcripts Analysis - Gufic Biosciences Ltd.

The concall transcripts of Gufic Biosciences provide valuable insights into the company's performance, strategy, and future outlook. Investors can access the concall transcripts on our website, where we provide downloadable transcripts of the company's earnings calls.

Reviewing the concall transcripts helps investors understand management's perspective and their plans to drive future growth. These transcripts serve as a valuable resource for long-term investors seeking a deeper understanding of Gufic Biosciences' business operations.

Investor Presentations Analysis - Gufic Biosciences Ltd.

Gufic Biosciences regularly conducts investor presentations to showcase its achievements, growth plans, and future prospects. These presentations provide detailed information about the company's business model, product portfolio, and market opportunities.

Investors can access these investor presentations on our website, where we provide downloadable copies. Reviewing these presentations can help investors gain valuable insights into Gufic Biosciences' strategic initiatives, competitive advantages, and potential investment opportunities.

Promoters and Shareholders Analysis - Gufic Biosciences Ltd.

Gufic Biosciences has a strong base of promoters and shareholders who have played a vital role in the company's success. Understanding the key stakeholders and their holdings can provide insights into the confidence placed in Gufic Biosciences by industry experts and institutional investors.

While we do not provide specific details of individual promoters and shareholders, our website offers resources that help investors understand the ownership structure and the influence of key stakeholders on Gufic Biosciences' decision-making processes.

In conclusion, Gufic Biosciences Ltd. is a reputable pharmaceutical company that offers innovative healthcare products. Investors interested in long-term stock analysis can utilize our website for comprehensive insights into the company's profile, share price, balance sheet, annual reports, dividend history, quarterly results, stock price, news updates, concall transcripts, investor presentations, and key stakeholders. Our pre-built screening tools and premium features enable investors to perform in-depth analysis and fair value calculations, assisting in informed investment decision-making. 

Gufic Biosciences Balance Sheet Overview

Gufic Biosciences' Growing Equity Reserves

From March 2020 to March 2024, Gufic Biosciences has shown a significant increase in its total reserves, jumping from Rs 119.63 Cr in March 2020 to Rs 522.53 Cr by March 2024. This growth indicates a solid reinforcement of the company's equity base, reflecting its enhanced financial strength and capability to sustain and expand its operations.

Gufic Biosciences' Debt Profile

The debt profile of Gufic Biosciences has seen dynamic changes over the past few years. Borrowings peaked at Rs 190.68 Cr in March 2023 before reducing to Rs 153.96 Cr by March 2024. This fluctuation in borrowing reflects the company's debt management strategy and its response to changing financial requirements and market conditions.

Gufic Biosciences' Asset Growth

Asset growth is a crucial indicator of a company's financial health and operational expansion. Gufic Biosciences' total assets have shown a remarkable increase from Rs 406.88 Cr in March 2020 to Rs 1,092.54 Cr by March 2024. Significant investments in capital work-in-progress (WIP) from Rs 30.61 Cr in March 2020 to Rs 307.06 Cr by March 2024, highlight the company's focus on expanding its operational capabilities and future growth prospects.

Analysis for the Standalone Balance Sheet of the Company

In addition to the detailed balance sheet analysis, investors and stakeholders closely monitor stock performance, market indices, and the company's sectoral dynamics for informed decision-making.

Read More
X